Vertex Pharmaceuticals 8-K

Summary

Vertex’s acquisition of Crinetics Pharmaceuticals. Vertex will acquire all outstanding shares for $85 per share in cash, valuing Crinetics at $10.0B, or $8.8B net of cash. The companies expect the deal to close in Q3 2026; Crinetics’ PALSONIFY and atumelnant are the strategic assets behind the stated revenue opportunity.

Key Figures

• Consideration: $85 per share in cash; $10.0B equity valuation, or $8.8B net of cash. Both companies’ boards unanimously approved the transaction.
• Financing: Vertex expects to use cash on hand and a $4.5B unsecured bridge facility, an aggregate principal commitment for 364 days, with an unsecured delayed-draw term loan expected as permanent financing. The merger has no financing condition.
• Closing conditions include Crinetics stockholder approval and regulatory clearances. A $350M termination fee may be payable by Crinetics in specified circumstances, including accepting a superior proposal.

Guidance

• Vertex said its 2026 guidance will be updated at the anticipated Q3 2026 closing; the deal is expected to have a modest impact on 2026 revenue and non-GAAP operating expenses.

Investor Takeaways

• Watch for Crinetics stockholder approval, regulatory clearances and completion in the expected Q3 2026 window.
• Vertex’s updated 2026 guidance at closing will clarify the near-term financial impact; the longer-term markers are more than $5B in potential annual peak revenue from Crinetics’ assets and expected non-GAAP operating income accretion in 2029.